Cohance Lifesciences Ltd

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 May 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 08 June 2026, providing investors with the latest perspective on the company’s position.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

The Sensex edged up 0.51% on 19 May 2026, but Cohance Lifesciences Ltd outpaced the broader market with a robust 7.57% gain, marking a 4.75 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers. This sharp intraday advance rewrites the short-term narrative for the small-cap stock, raising questions about whether this is a genuine recovery or a technical bounce within a mixed trend.

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reported a further deterioration in its financial performance for the quarter ended March 2026. Despite a marginal improvement in its financial trend score, the company continues to face significant headwinds, with sharp declines in profitability and sales growth contrasting starkly with broader market benchmarks.

Cohance Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Cohance Lifesciences Ltd has experienced a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting changing market perceptions amid a challenging sector backdrop. Despite a recent downgrade in its Mojo Grade to Sell, the company’s valuation metrics and comparative analysis against peers reveal nuanced insights for investors navigating the Pharmaceuticals & Biotechnology space.

Cohance Lifesciences Ltd., formerly known as Suven Pharmaceuticals, reported a sharp 83.77% year-on-year decline in consolidated net profit for Q4 FY26, posting ₹19.55 crores compared to ₹120.43 crores in the same quarter last year. The integrated Contract Development and Manufacturing Operations (CDMO) company, with a market capitalisation of ₹17,325 crores, saw its shares tumble 5.69% to ₹458.10 following the results announcement, reflecting investor concern over deteriorating profitability metrics.

Cohance Lifesciences Ltd witnessed a sharp gap down at the opening bell on 13 May 2026, reflecting heightened market apprehension. The stock opened with an 8.21% decline, underperforming its sector and broader indices as investors digested overnight developments and adjusted positions accordingly.

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish signals on weekly charts, monthly indicators suggest caution, reflecting a complex technical landscape for investors to navigate.

Cohance Lifesciences Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a modest day gain of 0.82%, the stock remains under pressure with a MarketsMOJO Mojo Score of 38.0 and a Sell grade, signalling cautious investor sentiment amid volatile market conditions.

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a significant surge in trading activity on 6 May 2026, driven by high-value turnover and notable institutional interest. The stock outperformed its sector and broader market indices, signalling renewed investor confidence despite a recent downgrade in its mojo grade.

The Sensex gained a modest 0.52% on 6 May 2026, while Cohance Lifesciences Ltd surged 8.78%, reaching an intraday high of Rs 498.05. This 8.05-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market lift.